Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of micafungin (FK463)
versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic
patients with confirmed invasive candidiasis or candidemia. Enrollment will include adult and
pediatric patients.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Amphotericin B Echinocandins Liposomal amphotericin B Micafungin